PURPOSE: Activation of coagulation and fibrinolysis is frequently found among cancer patients. Such tumors are considered to be associated with a higher risk of invasion, metastases, and eventually, worse outcome. The aim of this study is to explore the clinical and prognostic value of blood coagulation tests in gastric cancer (GC) patients. MATERIALS AND METHODS: A total of 44 consecutive patients with a pathologically confirmed diagnosis of GC were enrolled into the study. Pretreatment blood coagulation tests including prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), D-dimer (DD), fibrinogen (F) levels, and platelet (PLT) counts were evaluated. Control group comprised 50 age- and sex-matched individuals without history of malignancy and coagulation disorder. RESULTS: Median age at diagnosis was 55 years, range 19-80 years; most had men (n = 32, 73 %) and metastatic disease (n = 31, 70 %). The level of blood coagulation tests showed a statistically significant difference between the patient and the control groups (P < 0.001 for all, but p = 0.07 for PT). DD levels were significantly associated with elevated PLT and LDH levels (p = 0.009 and p = 0.01, respectively). Patients with metastatic disease had higher levels of F (p = 0.001) and INR (p = 0.027) levels. Elevated DD levels tended to be a poor prognostic factor on outcome (p = 0.06). CONCLUSION: Change in almost all coagulation tests are found in GC patients and only DD level seems to be of prognostic value.
PURPOSE: Activation of coagulation and fibrinolysis is frequently found among cancerpatients. Such tumors are considered to be associated with a higher risk of invasion, metastases, and eventually, worse outcome. The aim of this study is to explore the clinical and prognostic value of blood coagulation tests in gastric cancer (GC) patients. MATERIALS AND METHODS: A total of 44 consecutive patients with a pathologically confirmed diagnosis of GC were enrolled into the study. Pretreatment blood coagulation tests including prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), D-dimer (DD), fibrinogen (F) levels, and platelet (PLT) counts were evaluated. Control group comprised 50 age- and sex-matched individuals without history of malignancy and coagulation disorder. RESULTS: Median age at diagnosis was 55 years, range 19-80 years; most had men (n = 32, 73 %) and metastatic disease (n = 31, 70 %). The level of blood coagulation tests showed a statistically significant difference between the patient and the control groups (P < 0.001 for all, but p = 0.07 for PT). DD levels were significantly associated with elevated PLT and LDH levels (p = 0.009 and p = 0.01, respectively). Patients with metastatic disease had higher levels of F (p = 0.001) and INR (p = 0.027) levels. Elevated DD levels tended to be a poor prognostic factor on outcome (p = 0.06). CONCLUSION: Change in almost all coagulation tests are found in GC patients and only DD level seems to be of prognostic value.
Authors: I Tramacere; E Negri; C Pelucchi; V Bagnardi; M Rota; L Scotti; F Islami; G Corrao; C La Vecchia; P Boffetta Journal: Ann Oncol Date: 2011-05-02 Impact factor: 32.976
Authors: Esther Zorio; Juan Gilabert-Estellés; Francisco España; Luis A Ramón; Raul Cosín; Amparo Estellés Journal: Curr Med Chem Date: 2008 Impact factor: 4.530
Authors: Mari Tinholt; Marte Kathrine Viken; Anders Erik Dahm; Hans Kristian Moen Vollan; Kristine Kleivi Sahlberg; Oystein Garred; Anne-Lise Børresen-Dale; Anne Flem Jacobsen; Vessela Kristensen; Ida Bukholm; Rolf Kåresen; Ellen Schlichting; Grethe Skretting; Benedicte Alexandra Lie; Per Morten Sandset; Nina Iversen Journal: BMC Cancer Date: 2014-11-19 Impact factor: 4.430